Alzamend Neuro (NASDAQ:ALZN) Shares Up 2.5%

Alzamend Neuro, Inc. (NASDAQ:ALZNGet Free Report) shares traded up 2.5% during trading on Tuesday . The company traded as high as $0.91 and last traded at $0.89. 10,198 shares were traded during mid-day trading, a decline of 68% from the average session volume of 32,360 shares. The stock had previously closed at $0.87.

Alzamend Neuro Stock Performance

The firm’s 50-day moving average price is $0.95 and its two-hundred day moving average price is $2.67. The stock has a market cap of $6.34 million, a price-to-earnings ratio of -0.59 and a beta of -0.13.

Alzamend Neuro (NASDAQ:ALZNGet Free Report) last posted its earnings results on Friday, December 15th. The company reported $0.44 EPS for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ALZN. Renaissance Technologies LLC acquired a new stake in shares of Alzamend Neuro during the fourth quarter worth about $28,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Alzamend Neuro during the fourth quarter worth approximately $30,000. HRT Financial LP acquired a new stake in Alzamend Neuro during the 4th quarter worth $32,000. Virtu Financial LLC purchased a new position in Alzamend Neuro during the 4th quarter worth $35,000. Finally, Bank of America Corp DE purchased a new stake in shares of Alzamend Neuro in the first quarter valued at about $35,000. 6.37% of the stock is owned by institutional investors and hedge funds.

Alzamend Neuro Company Profile

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Recommended Stories

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with's FREE daily email newsletter.